SAN FRANCISCO, Jan. 5, 2017 /PRNewswire/ -- Nektar
Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer,
Howard W. Robin, is scheduled to
present at the upcoming 35th Annual J.P. Morgan Healthcare
Conference in San Francisco on
Tuesday, January 10, 2017 at
2:00 p.m. Pacific Time.
The presentation will be accessible via a Webcast through a link
posted on the Investor Relations, Events Calendar section of the
Nektar website: http://www.nektar.com. In addition, the company
will webcast the Q&A breakout session immediately following its
presentation at 2:30 p.m. Pacific Time. This Webcast will be
available for replay until February 17,
2017.
About Nektar
Nektar Therapeutics has a robust R&D pipeline and
portfolio of approved partnered medicines in oncology, pain,
immunology and other therapeutic areas. In the area of
oncology, Nektar is developing NKTR-214, an
immuno-stimulatory CD122-biased agonist, that is in Phase 1/2
clinical development for patients with solid tumors. ONZEALD™
(etirinotecan pegol), a long-acting topoisomerase I inhibitor, is
being developed for patients with advanced breast cancer and brain
metastases and is partnered with Daiichi Sankyo in Europe. In
the area of pain, Nektar has an exclusive worldwide
license agreement with AstraZeneca for MOVANTIK™ (naloxegol), the
first FDA-approved once-daily oral peripherally-acting
mu-opioid receptor antagonist (PAMORA) medication for the treatment
of opioid-induced constipation (OIC), in adult patients with
chronic, non-cancer pain. The product is also approved in
the European Union as MOVENTIG® (naloxegol) and is
indicated for adult patients with OIC who have had an inadequate
response to laxatives. The AstraZeneca agreement also includes
NKTR-119, an earlier stage development program that is a
co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly owned
mu-opioid analgesic molecule for chronic pain conditions, is in
Phase 3 development. In hemophilia, Nektar has a
collaboration agreement with Baxalta for ADYNOVATE™ [Antihemophilic
Factor (Recombinant)], a longer-acting PEGylated Factor VIII
therapeutic approved in the U.S. and Japan for
patients over 12 with hemophilia A. In anti-infectives, the company
has two collaborations with Bayer Healthcare, Cipro Inhale in
Phase 3 for non-cystic fibrosis bronchiectasis and Amikacin Inhale
in Phase 3 for patients with Gram-negative pneumonia.
Nektar's technology has enabled nine approved products in
the U.S. or Europe through partnerships with
leading biopharmaceutical companies, including AstraZeneca's
MOVANTIK™, Baxalta's ADYNOVATE™, UCB's Cimzia® for Crohn's disease
and rheumatoid arthritis, and Amgen's Neulasta® for
neutropenia.
Nektar is headquartered in San
Francisco, California, with additional operations
in Huntsville, Alabama and Hyderabad, India.
Further information about the company and its drug development
programs and capabilities may be found online
at http://www.nektar.com.
MOVANTIK™ is a trademark and MOVENTIG® is a registered trademark
of the AstraZeneca group of companies; ADYNOVATE™ is a trademark of
Baxalta Inc.; Cimzia® is a registered trademark of UCB; ONZEALD™ is
a trademark of Nektar Therapeutics.
CONTACT: Jennifer Ruddock of Nektar Therapeutics,
+1-415-482-5585
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-35th-annual-jp-morgan-healthcare-conference-in-san-francisco-ca-300386331.html
SOURCE Nektar Therapeutics